MC 509
Alternative Names: MC-509; MC509 XXLatest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator ViroCure
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in South Korea
- 19 Aug 2020 MC 509 is available for licensing as of 19 Aug 2020. https://www.virocure.net/technology
- 19 Aug 2020 Virocure has patent protection for MC 509 in South Korea, China and Japan (Virocure pipeline, September 2020).